Determining the effect of Selenium supplementation on CD4+ T lymphocyte count in HIV+ patients refered to Iranian HIV/AIDS Research Center (IRCHA)
Phase 3
- Conditions
- HIV infection.Unspecified human immunodeficiency virus [HIV] disease
- Registration Number
- IRCT138904244380N2
- Lead Sponsor
- Vice Chancellor For Research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Inclusion Criteria: Age 18-60 years, Confirmed HIV-1 infection with western blot test, receiving HAART, CD4 between 200 and 350, signing informed consent Exclusion criteria: Pregnancy, any other supplementation than Selinium, history of hypersensitivity to Selenium, unwilling to cooperate, any plan to leave Tehran during the next 9 months after beginning of the study, History of chronic kidney diseases
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CD4+ T cell count. Timepoint: Baseline, every 3 months up to the end of the study. Method of measurement: flowcytometry.
- Secondary Outcome Measures
Name Time Method Serum Selenium level. Timepoint: Baseline and at the end of the study. Method of measurement: Atomic absorption spectrometry.;Body mass index. Timepoint: Baseline and at the end of the study. Method of measurement: weight(kg)/height(m)×height(m).;Blood hemoglobin. Timepoint: Baseline and at the end of the study. Method of measurement: CBC test.;Rate of opportunistic infections. Timepoint: Every month during the study. Method of measurement: Medical history and physical examination.